Cowen & Co. analyst Chris Shibutani maintained a Buy rating on Aduro BioTech (ADRO) yesterday. The company’s shares closed yesterday at $1.94, close to its 52-week low of $1.81.
According to TipRanks.com, Shibutani is a 3-star analyst with an average return of 0.7% and a 42.9% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Five Prime Therapeutics, and Pieris Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aduro BioTech with a $8 average price target, a 312.4% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $7 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.99 and a one-year low of $1.81. Currently, Aduro BioTech has an average volume of 446.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes.
